Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24675890 | 0.87 | GLS (0.45) | CNR1CNR2 | |
| SCHEMBL24674865 | 0.83 | KDM4E (0.43) | KDM4ECYP2D6 | |
| SCHEMBL24675197 | 0.83 | KDM4E (0.43) | KDM4ECYP2D6 | |
| SCHEMBL24675795 | 0.82 | GLS (0.47) | CNR1CNR2 | |
| SCHEMBL24675764 | 0.82 | GLS (0.47) | CNR1CNR2 | |
| SCHEMBL25250103 | 0.81 | CYP2D6 (0.45) | CNR1CNR2CYP2D6 | |
| SCHEMBL24675190 | 0.78 | KDM4E (0.42) | KDM4EMAPK1PLA2G4B | |
| SCHEMBL25289842 | 0.78 | GLS (0.46) | CNR1CNR2 | |
| SCHEMBL30490889 | 0.78 | GLS (0.46) | CNR1CNR2 | |
| SCHEMBL30490842 | 0.76 | GLS (0.43) | CYP2D6PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022159688-A9 | DEGRADERS OF GRK2 AND USES THEREOF | SONATA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022159688-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |